Reuters logo
8 months ago
BRIEF-Ionis and Astrazeneca advance first generation 2.5 lica drug into preclinical development
December 19, 2016 / 11:09 PM / 8 months ago

BRIEF-Ionis and Astrazeneca advance first generation 2.5 lica drug into preclinical development

Dec 19 (Reuters) - Ionis Pharmaceuticals Inc :

* Says in conjunction with this milestone, Ionis earned a $25 million milestone payment from Astrazeneca

* Ionis and astrazeneca advance first generation 2.5 Lica drug into preclinical development to treat cardiovascular disease

* Advanced its lead drug candidate Ionis-AZ4-2.5-l(rx), which has now been renamed AZD8233, into preclinical development Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below